Long-Term Outcomes after Switching to Tenofovir Alafenamide in Patients with Chronic Hepatitis B
We sought to determine the long-term outcomes of chronic hepatitis B (CHB) cases switching to tenofovir alafenamide (TAF, <i>n</i> = 104, median age = 63.5 years). Data at switching to TAF (baseline) and those at 1, 2, 3, 4, and 5 years from switching to TAF were compared. At baseline, H...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/25/4/2245 |
| _version_ | 1797298019819847680 |
|---|---|
| author | Tomohiro Nishikawa Masahiro Matsui Saori Onishi Kosuke Ushiro Akira Asai Soo-Ki Kim Hiroki Nishikawa |
| author_facet | Tomohiro Nishikawa Masahiro Matsui Saori Onishi Kosuke Ushiro Akira Asai Soo-Ki Kim Hiroki Nishikawa |
| author_sort | Tomohiro Nishikawa |
| collection | DOAJ |
| description | We sought to determine the long-term outcomes of chronic hepatitis B (CHB) cases switching to tenofovir alafenamide (TAF, <i>n</i> = 104, median age = 63.5 years). Data at switching to TAF (baseline) and those at 1, 2, 3, 4, and 5 years from switching to TAF were compared. At baseline, HB envelop antigen (HBeAg) seropositivity was found in 20 patients (19.2%), and undetectable HBV-DNA in 77 patients (74.0%). Percentage of detectable HBV-DNA significantly reduced at any time point. HB surface antigen (HBsAg) levels significantly reduced at 3, 4, and 5 years. The percentage of HBeAg seropositivity significantly reduced at 5 years. HB core related antigen levels did not significantly change. In patients with baseline HbeAg seropositivity, HbsAg levels significantly reduced at any time point, and a similar trend was found in patients without HBeAg seropositivity. In patients with baseline FIB4 index >1.85, HBsAg levels significantly reduced at 3, 4, and 5 years, and in patients with baseline FIB4 index <1.85, HBsAg levels significantly reduced at any time point. The estimated glomerular filtration rate significantly reduced only at 5 years. The discontinuation rate owing to the side effects of TAF was 0%. In conclusion, switching to TAF therapy in patients with CHB may be effective and safe at least up to 5 years. |
| first_indexed | 2024-03-07T22:28:43Z |
| format | Article |
| id | doaj.art-84599d4ec9814a939a5dc7a46f11c736 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-07T22:28:43Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-84599d4ec9814a939a5dc7a46f11c7362024-02-23T15:20:19ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672024-02-01254224510.3390/ijms25042245Long-Term Outcomes after Switching to Tenofovir Alafenamide in Patients with Chronic Hepatitis BTomohiro Nishikawa0Masahiro Matsui1Saori Onishi2Kosuke Ushiro3Akira Asai4Soo-Ki Kim5Hiroki Nishikawa6Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, JapanSecond Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, JapanSecond Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, JapanSecond Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, JapanSecond Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, JapanDepartment of Gastroenterology, Kobe Asahi Hospital, Kobe 653-8501, JapanSecond Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, JapanWe sought to determine the long-term outcomes of chronic hepatitis B (CHB) cases switching to tenofovir alafenamide (TAF, <i>n</i> = 104, median age = 63.5 years). Data at switching to TAF (baseline) and those at 1, 2, 3, 4, and 5 years from switching to TAF were compared. At baseline, HB envelop antigen (HBeAg) seropositivity was found in 20 patients (19.2%), and undetectable HBV-DNA in 77 patients (74.0%). Percentage of detectable HBV-DNA significantly reduced at any time point. HB surface antigen (HBsAg) levels significantly reduced at 3, 4, and 5 years. The percentage of HBeAg seropositivity significantly reduced at 5 years. HB core related antigen levels did not significantly change. In patients with baseline HbeAg seropositivity, HbsAg levels significantly reduced at any time point, and a similar trend was found in patients without HBeAg seropositivity. In patients with baseline FIB4 index >1.85, HBsAg levels significantly reduced at 3, 4, and 5 years, and in patients with baseline FIB4 index <1.85, HBsAg levels significantly reduced at any time point. The estimated glomerular filtration rate significantly reduced only at 5 years. The discontinuation rate owing to the side effects of TAF was 0%. In conclusion, switching to TAF therapy in patients with CHB may be effective and safe at least up to 5 years.https://www.mdpi.com/1422-0067/25/4/2245chronic hepatitis Btenofovir alafenamideswitchefficacysafety |
| spellingShingle | Tomohiro Nishikawa Masahiro Matsui Saori Onishi Kosuke Ushiro Akira Asai Soo-Ki Kim Hiroki Nishikawa Long-Term Outcomes after Switching to Tenofovir Alafenamide in Patients with Chronic Hepatitis B International Journal of Molecular Sciences chronic hepatitis B tenofovir alafenamide switch efficacy safety |
| title | Long-Term Outcomes after Switching to Tenofovir Alafenamide in Patients with Chronic Hepatitis B |
| title_full | Long-Term Outcomes after Switching to Tenofovir Alafenamide in Patients with Chronic Hepatitis B |
| title_fullStr | Long-Term Outcomes after Switching to Tenofovir Alafenamide in Patients with Chronic Hepatitis B |
| title_full_unstemmed | Long-Term Outcomes after Switching to Tenofovir Alafenamide in Patients with Chronic Hepatitis B |
| title_short | Long-Term Outcomes after Switching to Tenofovir Alafenamide in Patients with Chronic Hepatitis B |
| title_sort | long term outcomes after switching to tenofovir alafenamide in patients with chronic hepatitis b |
| topic | chronic hepatitis B tenofovir alafenamide switch efficacy safety |
| url | https://www.mdpi.com/1422-0067/25/4/2245 |
| work_keys_str_mv | AT tomohironishikawa longtermoutcomesafterswitchingtotenofoviralafenamideinpatientswithchronichepatitisb AT masahiromatsui longtermoutcomesafterswitchingtotenofoviralafenamideinpatientswithchronichepatitisb AT saorionishi longtermoutcomesafterswitchingtotenofoviralafenamideinpatientswithchronichepatitisb AT kosukeushiro longtermoutcomesafterswitchingtotenofoviralafenamideinpatientswithchronichepatitisb AT akiraasai longtermoutcomesafterswitchingtotenofoviralafenamideinpatientswithchronichepatitisb AT sookikim longtermoutcomesafterswitchingtotenofoviralafenamideinpatientswithchronichepatitisb AT hirokinishikawa longtermoutcomesafterswitchingtotenofoviralafenamideinpatientswithchronichepatitisb |